Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
Status:
Terminated
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
The object of this study is to evaluate the pharmacokinetic interactions, short term safety
and efficacy of standard dose lopinavir/ritonavir 200mg/50 (two tablets twice daily) given
with ritonavir 100 mg three tablets twice daily given in combination with rifampin in
HIV-infected persons with tuberculosis